| Literature DB >> 25046533 |
Marta Tajes1, Eva Ramos-Fernández, Xian Weng-Jiang, Mònica Bosch-Morató, Biuse Guivernau, Abel Eraso-Pichot, Bertrán Salvador, Xavier Fernàndez-Busquets, Jaume Roquer, Francisco J Muñoz.
Abstract
The blood-brain barrier (BBB) is constituted by a specialized vascular endothelium that interacts directly with astrocytes, neurons and pericytes. It protects the brain from the molecules of the systemic circulation but it has to be overcome for the proper treatment of brain cancer, psychiatric disorders or neurodegenerative diseases, which are dramatically increasing as the population ages. In the present work we have revised the current knowledge on the cellular structure of the BBB and the different procedures utilized currently and those proposed to cross it. Chemical modifications of the drugs, such as increasing their lipophilicity, turn them more prone to be internalized in the brain. Other mechanisms are the use of molecular tools to bind the drugs such as small immunoglobulins, liposomes or nanoparticles that will act as Trojan Horses favoring the drug delivery in brain. This fusion of the classical pharmacology with nanotechnology has opened a wide field to many different approaches with promising results to hypothesize that BBB will not be a major problem for the new generation of neuroactive drugs. The present review provides an overview of all state-of-the-art of the BBB structure and function, as well as of the classic strategies and these appeared in recent years to deliver drugs into the brain for the treatment of Central Nervous System (CNS) diseases.Entities:
Keywords: Blood brain barrier; drug delivery; membrane transport
Mesh:
Substances:
Year: 2014 PMID: 25046533 DOI: 10.3109/09687688.2014.937468
Source DB: PubMed Journal: Mol Membr Biol ISSN: 0968-7688 Impact factor: 2.857